Table 3.
Univariate PFS analysis
| Median PFS | 1-year PFS (95% CI) | HR 95% CI | Cox P | |
|---|---|---|---|---|
| Risk group | ||||
| Favorable | 27.8 (14.8-90.2) | 100% | Reference | .22 |
| Intermediate | 16.4 (12.3-22.2) | 77.2% (53.7-89.8) | 2.10 (0.84, 5.30) | |
| Unfavorable | 31.8* | 100% | 0.82 (0.10, 6.88) | |
| Number of prior lines | ||||
| 1 line | 20.8 (13.5-90.2) | 87.1% (57.3-96.6) | Reference | .47 |
| 2 lines | 21.7 (10.7-27.8) | 80.0% (50.0-93.1) | 1.54 (0.68, 3.49) | |
| 3-5 lines | 31.8 (14.8-*) | 100% | 0.86 (0.23, 3.17) | |
| Type of systemic tx before RT† | ||||
| Immune checkpoint inhibitor | Not reached | 100% | Reference | .082 |
| VEGF inhibitor | 22.2 (15.2-33.8) | 84.9% (64.5-94.0) | 2.08 (0.48, 8.95) | |
| mTOR inhibitor | 13.4 (6.5-21.7) | 66.7% (5.4-94.5) | 6.98 (1.14, 42.91) | |
| Type of systemic tx on RT† | ||||
| Immune checkpoint inhibitor | Not reached | 100% | Reference | .26 |
| VEGF or mTOR inhibitor | 20.8 (14.8-31.8) | 83.1% (64.0-92.6) | 2.30 (0.54, 9.82 | |
| pT | ||||
| pT1 | 22.3 (8.9-90.2) | 83.3% (27.3-97.5) | Reference | .21 |
| pT2 | Not reached | 100% | 0.28 (0.03, 2.47) | |
| pT3 | 17.8 (13.4-27.8) | 81.0% (56.9-92.4) | 1.55 (0.52, 4.62) | |
| M | ||||
| M0 | 22.3 (15.4-33.8) | 85.0% (64.9-94.1) | Reference | .46 |
| M1 | 16.6 (10.7-35.4) | 88.9% (43.3-98.4) | 1.39 (0.58, 3.33) | |
| Number of mets at RT | ||||
| ≤5 | 31.8 (13.4-90.2) | 84.6% (51.2-95.9) | Reference | .15 |
| >5 | 20.8 (14.8-27.8) | 86.7% (64.3-95.5) | 1.87 (0.80, 4.35) | |
| Number of mets treated | ||||
| 1 | 22.2 (16.6-33.8) | 89.8% (71.5-96.6) | Reference | .24 |
| 2-3 | 13.6 (7.1-*) | 66.7% (19.5-90.4) | 1.80 (0.67, 4.80) | |
| Site of metastasis, bone | ||||
| Bone | 22.2 (12.3-33.8) | 81.9% (53.8-93.8) | 1.36 (0.63, 2.96) | .44 |
| Non-bone | 20.8 (16.3-42.8) | 89.5% (64.1-97.3) | Reference | |
| Site of metastasis, lung | ||||
| Lung | 50.0 (10.7-83.5) | 83.3% (27.3-97.5) | Reference | .59 |
| Non-lung | 21.7 (15.4-31.8) | 86.5% (68.0-94.7) | 1.34 (0.45, 3.97) |
Abbreviations: CI = confidence interval; HR = hazard ratio; mets = metastasis sites; mTOR = mechanistic target of rapamycin; VEGF = vascular endothelial growth factor; PFS = progression-free survival; pT = pathologic stage; RT = radiation therapy; tx = therapy.
⁎
Limit unable to be estimated.
†
The single patient receiving combination therapy was excluded.